Journal of Biotechnology and Biomedical Science

The Open Access Pub has the reputation for quick reviewing and publishing original research articles. The editorial boards of our journals have many dedicated and reputed scientists as editorial members. Their support helps many researchers from all countries to enhance their research between scientists of various communities. This platform plays a crucial role in promoting science networks and exchanges.

Dr. Bahgat Fayed, Associate Professor Of Molecular Microbiology And Nanoparticle Drug Delivery Expert.

United States

Associate Professor

Send an Email

Dr. Bahgat Fayed

Address:

National Research Centre (NRC), Giza, Egypt


Academic Metrics
  • h-index: 19
  • i10-index: 23
  • Total Citations Count: 807

Research Interests:

Dr. Fayed's research centers on innovative strategies for combating disease at the molecular and cellular level:

  • Antimicrobial Resistance And Biofilms
  • Nanoparticle Drug Delivery Systems
  • Molecular Microbiology And Biotechnology
  • Cancer Theranostics And Drug Repurposing
  • Heterologous Expression And Gene Clusters

Biography:

Dr. Bahgat Fayed is an Associate Professor specializing in Molecular Microbiology and Drug Delivery, with a focus on combating Antimicrobial Resistance. His research primarily investigates novel strategies utilizing nanoparticles (e.g., zinc oxide, chitosan) to disrupt microbial defenses, particularly Candida biofilms. Dr. Fayed’s work extends into cancer theranostics and the utilization of microbial and natural resources to produce antifungal peptides. He is committed to developing sustainable and eco-friendly therapeutic alternatives


Achievements

Dr. Fayed has been recognized for his research contributions in the biomedical field:

  • Fulbright Egyptian Scholar Program Alumnus.
  • His research on Nanoparticles vs. Candida Biofilms has been highlighted internationally.
     
Grants And Funding

Dr. Fayed's research is supported by institutional and international grants, though specific details are not always public:

  • Fulbright Program: Received support as a Fulbright Egyptian Scholar.
  • Active Funding: Continues to lead projects focused on antimicrobial resistance and cancer targeting.
     
Academic Profiles Of Dr. Bahgat Fayed

Explore his academic and professional presence across trusted platforms:

Publications:

Dr. Fayed's recent publications focus on utilizing nanotechnology and natural compounds to create effective strategies against drug-resistant pathogens and cancer cells.

The list of recent publications of Dr. Bahgat Fayed is listed below:
 

  1. Fayed, B., et al. (2023). Co-administration of amoxicillin-loaded chitosan nanoparticles and inulin: A novel strategy for mitigating antibiotic resistance and preserving microbiota balance in Helicobacter pylori treatment. International Journal Of Biological Macromolecules, 253, 126706. DOI: 10.1016/j.ijbiomac.2023.126706.
  2. Cagliani, R., Fayed, B., Jagal, J., Shakartalla, S. B., Soliman, S. S. M., & Haider, M. (2023). Peptide-functionalized zinc oxide nanoparticles for the selective targeting of breast cancer expressing placenta-specific protein 1. Colloids And Surfaces B: Biointerfaces, 227, 113357. DOI: 10.1016/j.colsurfb.2023.113357.
  3. Jagal, J., Cagliani, R., Kedia, R. A., Elsherbeny, A., Bayraktutan, H., & Fayed, B. (2023). Peptide-functionalized graphene oxide quantum dots as colorectal cancer theranostics. Journal Of Colloid And Interface Science, 630, 698-713. DOI: 10.1016/j.jcis.2022.10.126.
  4. Osman, R. B., Khoder, G., Fayed, B., Kedia, R. A., Elkareimi, Y., & Alharbi, N. (2023). Synthesis, characterization and antifungal activity of novel silver-piperazine/zinc oxide nanocomposites against clinical fungal pathogens. Polymers, 15(8), 1836. DOI: 10.3390/polym15081836.
  5. Holmes, J., Gaber, M., Jenks, M. Z., Wilson, A., Loy, T., Lepetit, C., & Fayed, B. (2023). Reversion of breast epithelial polarity alterations caused by obesity. NPJ Breast Cancer, 9(1), 35. DOI: 10.1038/s41598-025-07127-x.


 

Last Updated on September 30, 2025